fbpx

Profound Medical Corp

PROF

$7.38

Closing

▼-0.67%

1D

▼-13.07%

YTD

PROF

BBG0076T0BS9

Exchange

Sector

Market cap

$225.53M

Volume

21,536

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$225.53M

Analysts' Rating

BUY

Price Target (Mean)

14.54

Total Analysts

5

P/E

Operating Margin

-317.37%

Beta

0.84

Revenue Growth

63.89%

52 week high

$11.33

52 week low

$7.01

Div. Yield

%

EPS Growth

35.71

Company Profile

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.